12 December, 2017
Stephenson Harwood (Singapore) Alliance has advised Malaysia-headquartered Chemopharm Sdn Bhd., a leading pan-Southeast Asia medical devices distribution group, on the sale of a majority stake to the Everstone Group, via its platform Everlife.
Founded in 1976, Chemopharm is a major player in the Southeast Asia medical device/equipment market with operations across the region including Hong Kong, Indonesia, Singapore, the Philippines, Thailand and Vietnam. It provides products, solutions, and services for laboratory, analytical testing, life science and healthcare.
The Everstone Group is a premier India and Southeast Asia business group and multi asset investment firm with assets under management of approximately US$4 billion.
"Our role advising Chemopharm on this deal illustrates the strength of the firm's life sciences expertise, and our ability to advise in relation to complex multi-jurisdictional matters across Southeast Asia," said Singapore-based corporate partner Tom Platts, who led the transaction.
The Founder & CEO of Chemopharm, Mr C. A. Ooi, said: "The highly competent team at Stephenson Harwood has the right balance of commercial sense and technical legal knowledge. They managed the cross border elements of the transaction seamlessly and effectively, and were an integral part in leading us to completion of the transaction."
The Stephenson Harwood (Singapore) Alliance team was led by partner Tom Platts and senior associate Sheetal Sandhu, with support from of-counsel Helen Rhind-Hufnagel, associate Penelope Davey and trainees James Hammond and Sonali Shah.
